Publications by authors named "Leman Yel"

Claim this Profile
E
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases.
Niraj C Patel, Jolan E Walter, Richard L Wasserman, Arye Rubinstein, Suthida Kankirawatana, Leman Yel

J Clin Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy.
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel

Front Neurol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study.
Pauline M Ellerbroek, Leif G Hanitsch, Torsten Witte, Vassilios Lougaris, P Martin van Hagen, Leman Yel

Immunotherapy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study.
Peter Čižnár, Marion Roderick, Helen Schneiderova, Miloš Jeseňák, Gergely Kriván, Leman Yel

Allergy Asthma Clin Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy.
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel

Ann Clin Transl Neurol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
Arye Rubinstein, Mohsen Mabudian, Donald McNeil, Niraj C Patel, Richard L Wasserman, Leman Yel

J Clin Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kim Duff, Enrique Garcia, Leman Yel

J Clin Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Leman Yel

Immunother Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler, Leman Yel

Int Immunopharmacol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency.
Zhaoyang Li, Mitali Gaurav, Leman Yel

Pulm Pharmacol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel

J Clin Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler, Leman Yel

J Clin Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
Vera Bril, Robert D M Hadden, Thomas H Brannagan, Michal Bar, Elisabeth Chroni, Leman Yel

J Peripher Nerv Syst· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331].
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler, Leman Yel

Int Immunopharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies.
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler, Leman Yel

Int Immunopharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Biochemical Efficacy of an α-Proteinase Inhibitor (Aralast NP) in α-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis.
Zhaoyang Li, Ryan M Franke, Denise N Morris, Leman Yel

Pulm Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative biochemical efficacy analysis of an alpha-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency.
Zhaoyang Li, Ryan M Franke, Denise Morris, Leman Yel

Pulm Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study.
Michael Borte, Stefan Raffac, Martin Hrubiško, Karina Jahnz-Rozyk, Enrique Garcia, Leman Yel

Immunotherapy· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
Richard L Wasserman, Sudhir Gupta, Mark Stein, Christopher J Rabbat, Werner Engl, Leman Yel

Immunotherapy· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Zhaoyang Li, Todd Dumas, N Seth Berry, Barbara McCoy, Leman Yel

Int Immunopharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Zhaoyang Li, Barbara McCoy, Werner Engl, Leman Yel

J Clin Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.
Lisa M Meckley, Yanyu Wu, Diane Ito, Todd Berner, Barbara McCoy, Leman Yel

BMC Immunol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
Sudhir Gupta, Mark Stein, Iftikhar Hussain, Kenneth Paris, Werner Engl, Leman Yel

Ann Allergy Asthma Immunol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.
Daniel Suez, Gergely Kriván, Stephen Jolles, Mark Stein, Sudhir Gupta, Leman Yel

Immunotherapy· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Todd Dumas, N Seth Berry, Martin Wolfsegger, Stephen Jolles, Barbara McCoy, Leman Yel

Int Immunopharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis